Vaduganathan M, Mensah GA, et al. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–71.

Article  PubMed  Google Scholar 

Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.

Article  PubMed  PubMed Central  Google Scholar 

Banach M, Surma S. A look to the past - what has had the biggest impact on lipids in the last four decades? A personal perspective. Arch Med Sci. 2023;19(3):559–64.

CAS  PubMed  PubMed Central  Google Scholar 

Ference BA, Graham I, Tokgozoglu L, et al. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(10):1141–56.

Article  CAS  PubMed  Google Scholar 

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang N, Woodward M, Huffman MD, et al. Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2022;15(6):e008552.

Article  PubMed  Google Scholar 

Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

Article  CAS  PubMed  Google Scholar 

Hsu HY, Lin CJ, Lee YS, et al. Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2020;20(1):334.

Article  PubMed  PubMed Central  Google Scholar 

Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507–16.

Article  CAS  PubMed  Google Scholar 

Makover ME, Surma S, Banach M, et al. Eliminating atherosclerotic cardiovascular disease residual risk. Eur Heart J. 2023:ehad446.

Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17(6):1447–547.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banach M, Reiner Z, Cicero AFG, et al. 2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy. Arch Med Sci. 2022;18(6):1429–34.

PubMed  PubMed Central  Google Scholar 

Watts GF, Gidding SS, Hegele RA, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023; https://doi.org/10.1038/s41569-023-00892-0.

Nowowiejska-Wiewióra A, Wita K, Mędrala Z, et al. Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program. Kardiol Pol. 2023;81(4):359–65.

Article  PubMed  Google Scholar 

Banach M, Surma S, Kapłon-Cieślicka A, et al. Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association. Arch. Med. Sci. 2024;20(1):1–15.

Article  Google Scholar 

Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–89.

Article  PubMed  Google Scholar 

Vrablik M, Seifert B, Parkhomenko A, et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis. 2021;334:66–75.

Article  CAS  PubMed  Google Scholar 

Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624.

Article  PubMed  PubMed Central  Google Scholar 

Chiang CE, Ferrières J, Gotcheva NN, et al. Suboptimal control of lipid levels: results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb. 2016;23(5):567–87.

Article  CAS  PubMed  Google Scholar 

Nelson AJ, Haynes K, Shambhu S, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2022;79(18):1802–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banach M, López-Sendon JL, Averna M, et al. Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. Arch Med Sci. 2022;18(2):285–92.

Article  CAS  PubMed  Google Scholar 

Alonso R, Arroyo-Olivares R, Muñiz-Grijalvo O, et al. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study. Eur J Prev Cardiol. 2023;30(4):320–8.

Article  PubMed  Google Scholar 

Koenig W, Lorenz ES, Beier L, et al. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany. Clin Res Cardiol. 2023; https://doi.org/10.1007/s00392-023-02257-6.

Khachatryan A, Monga B, Sidelnikov E, et al. Association of adherence and treatment intensity of lipid-lowering therapy with cardiovascular outcomes and all-cause mortality in very high-risk patients in Germany. Eur Heart J. 2019;40:ehz747.0250.

Article  Google Scholar 

Rodriguez F, Maron DJ, Knowles JW, et al. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4(3):206–13.

Article  PubMed  PubMed Central  Google Scholar 

Desai NR, Farbaniec M, Karalis DG. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023;46(1):13–21.

Article  PubMed  Google Scholar 

Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213–23.

Article  PubMed  PubMed Central  Google Scholar 

Cheeley MK, Clegg K, Lockridge C, et al. Statin intolerance: an overview of US and international guidance. Curr Atheroscler Rep. 2023;25(8):517–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patti G, Spinoni EG, Grisafi L, et al. Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):138–47.

Article  PubMed  Google Scholar 

Karagiannis AD, Mehta A, Dhindsa DS, et al. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur Heart J. 2021;42(22):2154–69.

Article  CAS  PubMed  Google Scholar 

Sabouret P, Angoulvant D, Cannon CP, et al. Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate? Eur Heart J Open. 2022;2(4):oeac038.

Article  PubMed  PubMed Central  Google Scholar 

Banach M, Shekoohi N, Mikhailidis DP, et al. Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies (n = 355,591) and randomized controlled trials (n = 165,988). Arch Med Sci. 2022;18(4):912–29.

CAS  PubMed  PubMed Central  Google Scholar 

Ruscica M, Ferri N, Banach M, et al. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res. 2023;118(17):3288–304.

Article  PubMed  Google Scholar 

Surma S, Lewek J, Penson PE, et al. Statin intolerance: an overview for clinicians. In: Jenkins AJ, Toth PP, editors. Lipoproteins in Diabetes Mellitus. Contemporary Diabetes. Springer; 2023. p. 597–635.

Chapter  Google Scholar 

Toth PP, Granowitz C, Hull M, et al. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids Health Dis. 2019;18(1):175.

Article  PubMed  PubMed Central  Google Scholar 

Lin I, Sung J, Sanchez RJ, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm. 2016;22(6):685–98.

PubMed  Google Scholar 

Bradley CK, Wang TY, Li S, et al. Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry. J Am Heart Assoc. 2019;8(7):e011765.

Article  PubMed  PubMed Central  Google Scholar 

Rea F, Savaré L, Corrao G, et al. Adherence to lipid-lowering treatment by single-pill combination of statin and ezetimibe. Adv Ther. 2021;38(10):5270–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tokgözoğlu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022;43(34):3198–208.

Article  PubMed  PubMed Central  Google Scholar 

Yurtseven E, Ural D, Baysal K, et al. An update on the role of PCSK9 in atherosclerosis. J Atheroscler Thromb. 2020;27(9):909–18.

Article